Rheumatology in the Era of GLP-1 Medications

November 23, 2025

Article contributed by Prarthana Jain, DO MPH

With the growing use of GLP-1 receptor agonists, 2025 marked a transformative year for rheumatology. Originally developed for diabetes and weight management, GLP-1 medications, including semaglutide and tirzepatide, now intersect with the care of patients with inflammatory arthritis, osteoarthritis and systemic autoimmune disease. For rheumatology providers, understanding the benefits, challenges and evolving evidence surrounding these medications has become increasingly important in day-to-day practice.

Why GLP-1 Medications Matter to Rheumatology

Many patients seen in rheumatology clinics face comorbidities, such as obesity, metabolic syndrome and cardiovascular disease, that significantly impact musculoskeletal pain, inflammation and disease activity. GLP-1 medications have demonstrated measurable improvements across several of these domains:

Weight reduction leads to decreased mechanical load on weight-bearing joints and may improve osteoarthritis symptoms.
Reduced systemic inflammation observed in multiple studies, with downstream effects on pain and overall function.
Cardiometabolic benefits align with the elevated cardiovascular risk seen in rheumatoid arthritis, psoriatic disease and systemic lupus erythematosus.

As these therapies become more widely adopted, rheumatology providers are increasingly involved in interpreting their musculoskeletal implications and integrating them into care.

Clinical Insights for Rheumatology Providers

For patients with rheumatic disease, several important themes are emerging:

Osteoarthritis: Early evidence shows clinically meaningful improvements in knee and hip OA symptoms among patients who achieve significant weight loss with GLP-1 agents.
Inflammatory arthritis: Some patients report reduced morning stiffness and fatigue, possibly due to decreased adipose-driven cytokine activity.
Gout: GLP-1 medications may modestly reduce serum urate levels and promote weight loss.
Glucocorticoid-treated patients: Those with steroid-induced metabolic complications may particularly benefit from the cardiometabolic effects of GLP-1 therapy.

Rheumatology providers should also be aware of potential challenges:

GI side effects that may complicate the use of methotrexate or NSAIDs.
Volume depletion that may affect patients on diuretics or with chronic kidney disease.
Rare but important risks, including gallbladder disease or worsening diabetic retinopathy in susceptible patients.

Close coordination with primary care and endocrinology colleagues helps ensure shared understanding of when to continue, adjust or temporarily hold GLP-1 therapy during flares or procedures.

How Rheumatology Providers Can Be Involved

Rheumatology clinicians are increasingly at the center of conversations about GLP-1 therapy because of their unique perspective on pain, inflammation and systemic disease. We can support better patient outcomes by:

Screening for obesity-related risks and identifying patients who may benefit from metabolic therapy.
Monitoring musculoskeletal changes, including improvements in OA symptoms or new pain patterns that may accompany rapid weight loss.
Collaborating closely with primary care, endocrinology, nutrition and behavioral health to reinforce a cohesive, patient-centered approach.

Call to Action

As GLP-1 medications continue to expand in use, rheumatology providers have an important opportunity to guide patients through this changing landscape. By integrating metabolic health into routine rheumatologic care, strengthening multidisciplinary collaboration and staying informed on emerging evidence, we can help ensure that patients with rheumatic disease benefit fully from these therapies.